Characteristics of patients in the derivation and validation cohorts
| Category . | Derivation cohort, no. (%) . | Validation cohort, no. (%) . | P . |
|---|---|---|---|
| All patients | 2701 (100) | 1365 (100) | |
| All VTE | 60 (2.2) | 28 (2.1) | .72 |
| Age | .14 | ||
| Younger than 65 y | 1618 (59.9) | 850 (62.3) | |
| 65 y or older | 1083 (40.1) | 515 (37.7) | |
| Sex | .66 | ||
| Male | 882 (32.7) | 455 (33.3) | |
| Female | 1819 (67.3) | 910 (66.7) | |
| Performance status, ECOG | .54 | ||
| 0 to 1 | 2473 (91.6) | 1242 (91.0) | |
| 2 to 4 | 228 (8.4) | 123 (9.0) | |
| Primary site of cancer | .13 | ||
| Breast | 935 (34.6) | 472 (34.6) | |
| Colorectal | 297 (11.0) | 163 (11.9) | |
| Lung | 554 (20.5) | 236 (17.3) | |
| Gynecologic | 259 (9.6) | 142 (10.40) | |
| Gastric and pancreatic | 54 (2.0) | 19 (1.4) | |
| Lymphoma | 328 (12.1) | 184 (13.5) | |
| Other sites | 274 (10.1) | 149 (10.9) | |
| Stage | .06 | ||
| 1 to 3 | 1653 (61.2) | 873 (64.0) | |
| 4 | 997 (36.9) | 477 (34.9) | |
| Unknown | 51 (1.9) | 15 (1.1) | |
| Prior chemotherapy | 645 (23.9) | 306 (22.4) | .3 |
| Comorbidities | |||
| Cerebrovascular disease | 54 (2.0) | 23 (1.7) | .49 |
| Moderate or severe renal disease | 27 (1.0) | 18 (1.3) | .36 |
| Chronic pulmonary disease | 217 (8.0) | 110 (8.1) | .98 |
| Surgery within past month | 829 (30.7) | 473 (34.7) | .01 |
| Diabetes mellitus | 312 (11.6) | 169 (12.4) | .44 |
| BMI 35 kg/m2 or more | 332 (12.3) | 166 (12.2) | .90 |
| Baseline laboratory values | |||
| Platelet count 350 × 109/L or more | 604 (22.4) | 295 (21.6) | .59 |
| Hemoglobin level less than 100 g/L | 178 (6.6) | 73 (5.3) | .12 |
| WBC count more than 11 × 109/L | 344 (12.7) | 169 (12.4) | .75 |
| Bilirubin level more than 17.1 μmol/L | 103 (3.8) | 60 (4.4) | .37 |
| Albumin level less than 35 g/L | 544 (20.1) | 267 (19.6) | .66 |
| Creatinine level more than 114.4 μmol/L | 89 (3.3) | 45 (3.3) | .999 |
| Drugs | |||
| Erythropoiesis-stimulating agents reported up to cycle 2 | 764 (28.3) | 358 (26.2) | .17 |
| Prophylactic myeloid growth factors | 566 (21.0) | 299 (21.9) | .48 |
| Antibiotics | 131 (4.9) | 62 (4.5) | .66 |
| Corticosteroids | 712 (26.4) | 357 (26.2) | .89 |
| Category . | Derivation cohort, no. (%) . | Validation cohort, no. (%) . | P . |
|---|---|---|---|
| All patients | 2701 (100) | 1365 (100) | |
| All VTE | 60 (2.2) | 28 (2.1) | .72 |
| Age | .14 | ||
| Younger than 65 y | 1618 (59.9) | 850 (62.3) | |
| 65 y or older | 1083 (40.1) | 515 (37.7) | |
| Sex | .66 | ||
| Male | 882 (32.7) | 455 (33.3) | |
| Female | 1819 (67.3) | 910 (66.7) | |
| Performance status, ECOG | .54 | ||
| 0 to 1 | 2473 (91.6) | 1242 (91.0) | |
| 2 to 4 | 228 (8.4) | 123 (9.0) | |
| Primary site of cancer | .13 | ||
| Breast | 935 (34.6) | 472 (34.6) | |
| Colorectal | 297 (11.0) | 163 (11.9) | |
| Lung | 554 (20.5) | 236 (17.3) | |
| Gynecologic | 259 (9.6) | 142 (10.40) | |
| Gastric and pancreatic | 54 (2.0) | 19 (1.4) | |
| Lymphoma | 328 (12.1) | 184 (13.5) | |
| Other sites | 274 (10.1) | 149 (10.9) | |
| Stage | .06 | ||
| 1 to 3 | 1653 (61.2) | 873 (64.0) | |
| 4 | 997 (36.9) | 477 (34.9) | |
| Unknown | 51 (1.9) | 15 (1.1) | |
| Prior chemotherapy | 645 (23.9) | 306 (22.4) | .3 |
| Comorbidities | |||
| Cerebrovascular disease | 54 (2.0) | 23 (1.7) | .49 |
| Moderate or severe renal disease | 27 (1.0) | 18 (1.3) | .36 |
| Chronic pulmonary disease | 217 (8.0) | 110 (8.1) | .98 |
| Surgery within past month | 829 (30.7) | 473 (34.7) | .01 |
| Diabetes mellitus | 312 (11.6) | 169 (12.4) | .44 |
| BMI 35 kg/m2 or more | 332 (12.3) | 166 (12.2) | .90 |
| Baseline laboratory values | |||
| Platelet count 350 × 109/L or more | 604 (22.4) | 295 (21.6) | .59 |
| Hemoglobin level less than 100 g/L | 178 (6.6) | 73 (5.3) | .12 |
| WBC count more than 11 × 109/L | 344 (12.7) | 169 (12.4) | .75 |
| Bilirubin level more than 17.1 μmol/L | 103 (3.8) | 60 (4.4) | .37 |
| Albumin level less than 35 g/L | 544 (20.1) | 267 (19.6) | .66 |
| Creatinine level more than 114.4 μmol/L | 89 (3.3) | 45 (3.3) | .999 |
| Drugs | |||
| Erythropoiesis-stimulating agents reported up to cycle 2 | 764 (28.3) | 358 (26.2) | .17 |
| Prophylactic myeloid growth factors | 566 (21.0) | 299 (21.9) | .48 |
| Antibiotics | 131 (4.9) | 62 (4.5) | .66 |
| Corticosteroids | 712 (26.4) | 357 (26.2) | .89 |